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SLICC/DIAbstract Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease character-
ized by excessive autoantibody production against ‘self’ antigens and immunocomplex formation,
resulting in frequent widespread inﬂammatory damage to target multiple organ systems.
Aim of work: To determine the association of lymphopenia with the clinical manifestations,
serologic abnormalities, disease activity and disease damage as well as drug intake in SLE
patients.
Patients and methods: The present study was carried out on forty-ﬁve SLE female patients
fulﬁlling the American College of Rheumatology (ACR) revised criteria for the diagnosis of
SLE. They were divided into two groups according to the lymphocytes’ count: Group-I: thirty
patients with lymphopenia (<1500/mm3) and group-II: ﬁfteen patients without lymphopenia
(P1500/mm3). Ten healthy age matched females (group-III) taken as a control group. Patients
and control groups were recruited from the Rheumatology and Rehabilitation Department, Faculty
of Medicine, Cairo University Hospitals. Disease activity was assessed using the SLE Disease
Activity Index (SLEDAI). Disease damage was assessed with Systemic Lupus International
Collaborative Clinics/American College of Rheumatology (SLICC/ACR) damage index.
Results: Lymphopenia in patients with SLE was found to be associated with lupus nephritis
(p= 0.023), leucopenia (p= 0.004), increased disease activity index (p= 0.03) and increased organ
126 S. Faddah et al.damage index (p= 0.02), and was not associated with other clinical lupus manifestations, serolog-
ical abnormalities or with the drug intake (p> 0.05).
Conclusion: Lymphopenia in SLE was associated with lupus nephritis, leucopenia and increased
both disease activity and organ damage indices.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis. Open access under CC BY-NC-ND license.1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease
characterized by excessive autoantibody production against
‘self’ antigens and immunocomplex formation, resulting in
frequent widespread inﬂammatory damage to target multiple
organ systems. It may affect any organ and produce a broad
spectrum of clinical manifestations [1]. Lymphopenia is a com-
mon clinical manifestation in lupus [2,3] and the mechanism of
its occurrence is still unknown [2]. The clinical usefulness of
lymphopenia has been limited mainly to aid in lupus diagnosis
because lymphopenia is one of the hematologic criteria accord-
ing to the American College of Rheumatology (ACR) [4].
Lymphopenia was detected in about two thirds of lupus
patients on initial diagnosis and in more than 90% of patients
during their disease course [5]. Lymphopenia has been shown
to be associated with disease activity in adult SLE patients
[6,7]. However, it may be caused by factors other than SLE.
Medications including corticosteroids, cytotoxic agents, infec-
tions and hospital setting can also contribute to reduction in
lymphocyte count, which may not be a direct reﬂection of
disease activity [8]. Some studies have shown lymphopenia to
be associated with particular clinical manifestations of SLE,
disease activity and organ damage [1,6].
The aim of this study was to determine association of
lymphopenia with any of the clinical SLE manifestations, sero-
logic abnormalities, disease activity and disease damage index
as well as with the drug intake.2. Patients and methods
2.1. Patients
The present study was carried out on 45 SLE female patients
fulﬁlling the ACR revised criteria for the diagnosis of SLE
[4]. Full clinical examination was done to all patients. Routine
laboratory investigations including complete blood and differ-
ential count, erythrocyte sedimentation rate (ESR), liver and
kidney function tests, complete urine analysis, 24 h urinary
proteins and serum complement 3 and 4 (C3 & C4) levels were
done. Antinuclear (ANA), anti-double stranded DNA (anti-
ds-DNA), anti-cardiolipin IgG and IgM were measured by
enzyme linked immunosorbent assay to all patients. Radiolog-
ical investigations including abdominal and pelvic ultrasonog-
raphy, echocardiography and chest X-ray were also done to all
patients. Patients were divided into two groups according to
the lymphocytes’ count. Group-I included 30 patients with
lymphopenia (<1500/mm3) [9] and group-II included 15 pa-
tients without lymphopenia (P1500/mm3) [5]. Ten healthy
age matched females were taken as a control group. Patients
and control groups were recruited from the Rheumatology
and Rehabilitation Department, Faculty of Medicine,Cairo University Hospitals. Patients with other causes of lym-
phopenia were excluded from the study and this included pa-
tients with viral hepatitis, tuberculosis, history of malignancy
and previous treatment with either radiotherapy, chemother-
apy or both. Patients with end stage renal disease were also
excluded. All participants provided written informed consent
prior to their inclusion. This study was approved by the local
ethics committees and in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki.
2.2. Assessment of disease activity
It was assessed using the SLE Disease Activity Index (SLE-
DAI) [10]. It measures the potentially reversible underlying
inﬂammatory disease process in adult SLE patients. The ﬁnal
score comprises the sum of all weighted attributed scores.
The SLEDAI has a theoretically possible range of 0–105, with
0 being no disease activity. The activity was considered mild if
the score is 610, moderate if it was between 11 and 20, severe if
it was between 21 and 45 and very severe if it was 46 or more.
2.3. Assessment of organ damage
It is assessed at the time of the study using the systemic lupus
International Collaborating Clinics/American College of
Rheumatology (SLICC/ACR) damage index [11]. It is a mea-
surement of cumulative end organ damage in SLE. Damage is
described as non-reversible change, not related to the active
inﬂammation, occurring since the onset of lupus, ascertained
by clinical assessment, and present for at least 6 months unless
otherwise stated. The maximum possible total score is 47.
Statistical analysis: was performed using SPSS-11.0 (Statis-
tical Package for Scientiﬁc Studies) for Windows. Data were
tabulated and statistically analyzed to evaluate the difference
between the groups under the study as regards the various
parameters. The statistical analysis included: arithmetic mean,
standard deviation, Student’s unpaired ‘‘t’’ test, Chi-square
‘‘X2’’ test, and Post Hoc Scheffe test.
3. Results
Demographic data and clinical manifestations of all our lupus
patients mentioned in Table 1. Table 2 showed no statistically
signiﬁcant differences as regards the demographic data be-
tween group-I and group-II, which means that our patients
in the two groups were matched for age, age at disease onset
and disease duration. Tables 3 and 4 show that the nephritis
and leucopenia were the only signiﬁcant clinical and hemato-
logic manifestations associated with lymphopenia.
There were no statistically signiﬁcant differences of the
studied autoimmune antibodies among the two lupus patient
groups. ANA was found in 29 patients in group-I vs. 15
Table 1 Demographic data and clinical manifestations of all
systemic lupus erythematosus patients (45 patients).
Demographic and clinical manifestations No. (%)
Demographic data
Age (yrs.); range (mean ± SD) 20–43 yrs. (26.91 ± 6.91)
Age at disease onset, range (yrs.);
(mean ± SD)
19–40 yrs. (23.4 ± 5.86)
Disease duration, range (yrs.);
(mean ± SD)
1–16 yrs. (3.51 ± 3.33)
Constitutional manifestations
Fatigue 10 (22.22%)
Fever 23 (51.11%)
Weight loss 12 (26.66%)
Mucocutaneous manifestations
Malar rash 28 (62.22%)
Discoid rash 4 (8.88%)
Photosensitivity 23 (51.11%)
Oral ulcers 26 (57.77%)
Alopecia 3 (6.66%)
Joint manifestations
Arthralgia 5 (11.11%)
Arthritis 37 (82.22%)
Cardio-pulmonary manifestations
Pericardial eﬀusion 10 (22.22%)
Valvular disease 10 (22.22%)
Pleural eﬀusion 26 (57.77%)
Shrinking lung syndrome 1 (2.22%)
Pulmonary hypertension 6 (13.33%)
Vascular manifestations
Raynaud’s phenomenon 11 (24.44%)
Palpable purpura 3 (6.66%)
Levido reticularis 7 (15.55%)
Skin ulcers 4 (8.88%)
Thrombotic events 7 (15.55%)
Lupus nephritis 29 (64.44%)
Neuro-psychiatric manifestations
Mood disturbance 10 (22.22%)
Peripheral neuropathy 2 (4.44%)
Psychosis 5 (11.11%)
TIAs 2 (4.44%)
Stroke 2 (4.44%)
Seizures 7 (15.55%)
Hepatomegaly 10 (22.22%)
Splenomegaly 3 (6.66%)
yrs. = years; TIAs, transient ischemic attacks.
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DNA, was found in 27 vs. 12 patients (90% vs. 80%,
p= 0.352), aCL-IgG was found in 14 patients versus 8
(46.7% vs. 53.3%, p= 0.673) and aCL-IgM in 11patients vs.
8 (36.7% vs. 53.3%, p= 0.286).Table 2 Demographic data of systemic lupus erythematosus patien
II).
Demographic data Group-I range (mean ± SD)
Age 20–42 yrs. (26.87 ± 7.03 yrs.)
Age at disease onset 19–40 yrs. (23.53 ± 6.15 yrs.)
Disease duration 1–16 yrs. (3.33 ± 3.31 yrs.)The Table 5 shows the statistical comparison of laboratory
investigations between the two groups by using the Post Hoc
Scheffe test. Group-I had signiﬁcantly lower TLC
(p= 0.046) and lower lymphocyte count (p< 0.001) than
group-II.
There were no statistically signiﬁcant differences between
the group-I and group-II regarding prednisone (29 vs. 12,
p= 0.064), hydroxychloroquine (20 vs. 12, p= 0.352),
azathioprine (19 vs. 6, p= 0.138), methotrexate (only one in
group-II, p= 0.153), cyclophosphamide (3 vs. 1, p= 0.811)
or mycophenolate mofetil (2 only among group-I, p= 0.306).
3.1. SLEDAI score of patients
In group-I, SLEDAI score ranged from 2 to 28 with a mean of
14.07 ± 6.94. Thirteen (43.3%), 12 (40%) and 5 (16.7%)
patients had mild, moderate and severe disease activity respec-
tively. In group-II, SLEDAI score ranged from 0 to 22 with a
mean of 6.53 ± 5.37. Twelve (80%) patients had mild disease
activity. Moderate and severe disease activities were found in 1
(6.7%) patient for each, and 1 (6.7%) patient had a controlled
disease without activity at the time of the study. Group-I
showed a statistically signiﬁcant higher disease activity than
group-II (p= 0.03).
3.2. SLICC/ACR damage index of patients
The overall organ damage index among group-I ranged from 0
to 5 and among group-II ranged from 0 to 1. Group-I was
signiﬁcantly associated with more organ damage index
(p= 0.02) as shown in Table 6. Most of the organ damages
in group-I were related to renal complications due to end stage
renal disease; pulmonary complications that included shrink-
ing lung syndrome, pulmonary hypertension and interstitial
pulmonary ﬁbrosis; peripheral venous thrombosis; peripheral
neuropathy and to stroke. While, most of the organ damages
in group-II were related to pulmonary complications that
included pulmonary hypertension and interstitial pulmonary
ﬁbrosis and to seizures.4. Discussion
Lymphopenia is a common clinical manifestation and one of
the hematological criteria according to the ACR classiﬁcation
and diagnostic criteria of SLE [4]. The only SLE clinical man-
ifestation that was found to be statistically associated with
lymphopenia was the lupus nephritis, which was consistent
with the results of Vila et al. [6]. This can be explained by
Nakabayashi et al. [12]; who had found that patients with
SLE with active nephritis have high titers of anti-T-cell
antibodies, especially in proliferative glomerulonephritis.ts with lymphopenia (group I) and without lymphopenia (group
Group-II range (mean ± SD) p Value
20–43 yrs. (27 ± 6.92 yrs.) 0.952
19–37 yrs. (23.13 ± 5.46 yrs.) 0.826
1–14 yrs. (3.87 ± 3.46 yrs.) 0.625
Table 3 Clinical manifestations of systemic lupus erythematosus patients with lymphopenia (group-I) and without lymphopenia
(group-II).
Clinical manifestations Group-I No. (%) Group-II No. (%) p Value
Constitutional manifestations
Fatigue 7 (23.3%) 3 (20%) NA
Fever 17 (56.7) 6 (40%) 0.35
Weight loss 8 (26.7) 4 (26.7) NA
Mucocutaneous manifestations
Malar rash 18 (60%) 10 (66.7) 0.752
Discoid rash 3 (10%) 1 (6.7%) NA
Photosenstivity 12 (40%) 11 (73.3%) 0.057
Oral ulcers 18 (60%) 8 (53.3%) 0.754
Alopecia 2 (6.7%) 1 (6.7%) NA
Joint manifestations
Arthralgia 4 (13.3%) 1 (6.7%) 0.651
Arthritis 25 (83.3%) 12 (80%) NA
Cardiopulmonary manifestations
Pericardial eﬀusion 8 (26.7%) 2 (13.3%) 0.456
Valvular disease 9 (30%) 1 (6.7%) 0.129
Pleural eﬀusion 18 (60%) 8 (53.3%) 0.754
Shrinking lung syndrome 1 (3.3%) 0 NA
Pulmonary hypertension 5 (16.7%) 1 (6.7%) 0.647
Interstitial pulmonary ﬁbrosis 5 (16.7%) 1 (6.7%) 0.657
Vascular manifestations
Raynaud’s phenomenon 9 (30%) 2 (13.3%) 0.288
Palpable purpura 2 (6.7%) 1 (6.7%) NA
Livido reticularis 5 (16.7%) 2 (13.3%) NA
Skin ulcers 3(10%) 1 (6.7%) NA
Venous thrombotic events 5 (10%) 2 (13.3%) NA
Lupus nephritis 23 (76.7%) 6 (40%) 0.023
Neuro-psychiatric manifestations
Mood disturbance 8 (26.7%) 2 (13.3%) 0.456
Peripheral neuropathy 2 (6.7%) 0 NA
Psychosis 4 (13.3%) 1 (6.7%) 0.651
TIAs 1 (3.3%) 1 (6.7%) NA
Stroke 2 (6.7%) 0 NA
Seizures 3 (10%) 4 (26.7%) 0.199
Hepatomegaly 9 (30%) 1 (6.7%) 0.129
Splenomegaly 2 (6.7%) 1 (6.7%) NA
Mood disturbance included anxiety and depression, TIAs, transient ischemic attacks; NA, not applicable.
Table 4 Hematologic manifestations of systemic lupus erythematosus patients with lymphopenia (group I) and without lymphopenia
(group II).
Hematologic manifestations Group-I No. (%) Group-II No. (%) p Value
Hemolytic anemia 3 (10%) 0 0.54
Leucopenia 12 (40%) 0 0.004
3 (10%) 2 (13.3%) NAThrombocytopenia
NA, not applicable.
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in constitutional manifestations between lymphopenic and
non-lymphopenic patients. This is consistent with the results
of Vila et al. [6], but was in contrast with Wysenbeek et al.
[13] who had previously found that patients with fatigue had
signiﬁcantly lower lymphocyte counts, and Rivero et al. [14]who had found a signiﬁcantly higher prevalence of fever in pa-
tients with lymphopenia.
In our study, there was no statistically signiﬁcant difference
in mucocutaneous manifestations between lymphopenic and
non-lymphopenic patients. In contrast to our study, Yu et al.
[7] had reported in a retrospective study that lymphopenia
Table 5 Laboratory investigations of the systemic lupus erythematosus patients with lymphopenia (group I), without lymphopenia
(group II).
Items Group-I (mean ± SD) Group-II (mean ± SD) p Value
ESR 91.7 ± 42.85 mm/1st h 61.73 ± 38.4 mm/1st h 0.051
Hb 9.37 ± 1.67 mg/dl 10.5 ± 1.89 mg/dl 0.92
TLC 5.81 ± 2.65 · 103/mm3 7.91 ± 2.9 · 103/mm3 0.046
Lymphocytes 712.6 ± 296.65/mm3 2393.2 ± 623/mm3 0.000
PLT 304.5 ± 144.3 · 103/mm3 238 ± 93.14 · 103/mm3 0.226
ALT 21.83 ± 15.67 l/l 18.4 ± 6.03 l/l 0.68
Creatinine 1.32 ± 1.62 mg/dl 0.73 ± 0.5 mg/dl 0.33
24 h urinary protein 1.67 ± 1.76 g/day 1.04 ± 2.49 g/day 0.56
C3 0.71 ± 0.31 g/l 0.7 ± 0.45 g/l 0.99
C4 0.17 ± 0.16 g/l 0.13 ± 0.1 g/l 0.7
ESR, erythrocyte sedimentation rate; Hb, hemoglobin; TLC, total leucocytic count; PLT, platelets; ALT, alanine transaminase; C, complement.
Table 6 SLICC/ACR damage index score of the systemic lupus erythematosus patients with lymphopenia (group I), without
lymphopenia (group II).
SLICC/ACR damage index score Group-I No. (%) Group-II No. (%) p Value
0 8 (26.7%) 12 (80%) 0.02
1 9 (30%) 3 (20%)
2 5 (16.7%) 0
3 5 (16.7%) 0
4 1 (3.3%) 0
5 2 (6.7%) 0
SLICC/ACR: Systemic Lupus International Collaborative Clinics/American College of Rheumatology.
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diagnosis. Vila et al. [6] had found that lymphopenia was
negatively associated with photosensitivity.
In our study, there was no statistically signiﬁcant difference
in musculoskeletal manifestations between lymphopenic and
non-lymphopenic patients which is consistent with the results
of Vila et al. [6], but not with that of Rivero et al. [14].
Our results showed no statistically signiﬁcant difference
between lymphopenic and non-lymphopenic patients as
regards vascular manifestations in the form of palpable pur-
pura, livido reticularis, skin ulcers and peripheral venous
thrombotic events. In contrast, Drenkard et al. [15] had found
that vasculitis in SLE was associated with lymphopenia.
In our study, there was no statistically signiﬁcant difference
in neuropsychiatric manifestations (NPSLE) between lymp-
hopenic and non-lymphopenic patients which is consistent
with the results of Vila et al., [6]. In contrast, Rivero et al.
[14] had found that lymphopenia was associated with neuro-
logic involvement. Yu et al. [7] had reported that marked lym-
phopenia was independently associated with NPSLE. They
had explained it by the fact that anti-lymphocyte antibodies,
including anti-DNA and anti-ribosomal P antibodies were fre-
quently found in SLE patients [16,17]. Anti-ribosomal P anti-
bodies induce T-cell apoptosis, and they cross react with
neuron cells. Also, lymphocytes of NPSLE patients are more
susceptible to death by neglect apoptosis than non-NPSLE
patients [17,18].
In our study, there was no statistically signiﬁcant difference
in respiratory manifestations between lymphopenic and non-
lymphopenic patients. Yu et al. [7] had found that marked
lymphopenia was signiﬁcantly associated with serositiscompared with lymphocyte counts of more than 500/mm3.
But, Vila et al. [6] had reported that lymphopenia was not
associated with serositis.
In our study, there was no statistically signiﬁcant difference
in cardiovascular manifestations or gastrointestinal manifesta-
tions between lymphopenic and non-lymphopenic patients. No
other studies had reported an association.
As regards hematological manifestations, our results
showed that lymphopenia was associated with leucopenia but
not with hemolytic anemia or thrombocytopenia. In accor-
dance to our study, Vila et al. [6] and Yu et al. [7] had found
that lymphopenia was associated with leucopenia.
Regarding serological abnormalities, there were no signiﬁ-
cant differences between ANA, anti-DNA, aCL-IgG and
aCL-IgM among lymphopenic and non-lymphopenic patients.
In contrast, Vila et al. [6] had demonstrated that lymphopenia
was associated with anti-DNA antibodies but not with ANA,
aCL-IgG or aCL-IgM. Besides, Yu et al. [7] had found that
lymphopenia was associated with anti-DNA antibodies. These
anti-DNA antibodies may have lymphocytotoxic activity by
cross-reactivity between nuclear antigen and lymphocyte mem-
brane [16].
In our study, there were no statistically signiﬁcant differ-
ences in the intake of corticosteroids, hydroxychloroquine,
azathioprine, pulsed cyclophosphamide and mycophenolate
mofetil between lymphopenic and non-lymphopenic patients.
In contrast, Vila et al. [6] had found that lymphopenia was
associated with corticosteroids and azathioprine but not with
the pulsed cyclophosphamide or with hydroxychloroquine.
There was a high statistically signiﬁcant association
between lymphopenia and disease activity index which was
130 S. Faddah et al.consistent with the results of Vila et al. [6], Yu et al. [7] and
Mirzayan et al. [19]. This may be explained by that in active
SLE, lymphocyte apoptosis may result from activation
induced cell death via Fas and Fas ligand pathway [20,21] or
death by neglect-apoptosis [22]. Also, CD4+ and CD8+
T-cells that bear the CD28 molecule, a potent costimulatory
signal for T-cell activation, are decreased in the peripheral
blood of patients with SLE. It appears that CD28 mediated
costimulation inﬂuences T-cell susceptibility to activation in-
duced cell death and may be involved in T-cell lymphopenia
[20]. Also, anti-CD4 antibodies are frequently found in pa-
tients with SLE [23].
There was a high statistically signiﬁcant association
between lymphopenia and organ damage index which is con-
sistent with the results of Vila et al. [6] and Yu et al. [7]. This
may be explained ﬁrst by that lymphopenia was associated
with major organ involvement such as renal disease [6]. Also,
lymphopenia was related to disease activity which is an impor-
tant predictor of damage accrual [24].It is recommended to
continue this preliminary study over the next 3 years to include
more lupus patients with and without lymphopenia for more
expected signiﬁcant results.
In conclusion, SLE patients presenting with lymphopenia
at time of diagnosis and/or developing it during follow up
should draw our attention to serious clinical manifestations
that may be associated as lupus nephritis and to an increase
in disease activity and organ damage indices.
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